## **Supporting Information**

# 2 Appendix A. Exclusion Protocol

- For this secondary data analysis, we chose to exclude women with pregnancy outcomes including fetal death before 20 weeks gestation, elective termination, indicated termination, unknown outcomes, and if the participant refused to release to
- 5 indicated termination, unknown outcomes, and if the participant refused to release their

pregnancy outcome. We also excluded women who delivered at gestational age < 22

- 7 weeks or > 43 weeks. We excluded women who had an incomplete labor, delivery, and
- 8 postpartum form (form "CMA" in the nuMoM2b database) and those with an incomplete
- 9 across visit medical conditions and medications form (form "VXX" in the nuMoM2b
- database). 18 Finally, we excluded women without self-reported race/ethnicity status and
- those without mode of delivery recorded (Figure S1).

12

13

1

6

Figure S1: Exclusion Criteria

## **Appendix B: Methods**

14

15 **B.1 Data Preparation** The nuMoM2b study recruited individuals from hospitals affiliated with eight clinical 16 17 centers and collected data on each participant over the course of four study visits. Visit 1 occurred between 6 and 14 weeks, Visit 2 occurred between 16 and 22 weeks, Visit 3 18 19 occurred between 22 and 30 weeks, and Visit 4 occurred at the time of delivery. 20 21 In the nuMoM2b study, women's racial and ethnic status was self-reported during Visit 22 1, and women were given the option to select more than one racial category. In our 23 analysis, we used a single feature to represent race and ethnicity. We grouped maternal 24 race and ethnicity as non-Hispanic white, non-Hispanic Black, Hispanic, Asian, 25 multiracial, and other, where the "Other" category includes American Indian, Native 26 Hawaiian, and any other race/ethnicity status. 27 28 No features were missing at more than 20%, so none were removed. We imputed the 29 missing entries using multivariate imputation by chained equations (MICE),<sup>38</sup> an algorithm that preserves the distribution of each variable. Specifically, we used 30 predictive mean matching (PMM)<sup>38</sup> because this method imputes only values that are 31 32 observed and therefore preserves categorical variables. 33 34 **B.2 Primary Outcomes** 35 The outcome of "severe preeclampsia" in our study is indicated by one of the following 36 diagnoses from the nuMoM2b dataset: severe preeclampsia, superimposed 37 preeclampsia, or eclampsia. These diagnoses were identified through a detailed chart 38 review performed by a site investigator or staff member certified for abstraction of 39 complicated charts. If necessary, difficult cases were adjudicated by the principal 40 investigators and final classification was reached by consensus. The outcome of "blood 41 transfusion" is indicated by any amount of any blood product administered anytime 42 during pregnancy or postpartum (up to 14 days) as recorded in a participant's medical records. The occurrence of postpartum readmission is indicated by any readmission to 43 44 the hospital within 14 days of delivery. A detailed description of the nuMoM2b study

definitions of hypertensive orders is included as a supplement to the paper by Facco et

46 al. (2017).<sup>39</sup>

Table S1: Adverse maternal outcomes and their corresponding indicators in the nuMoM2b dataset

Adverse Maternal	nuMoM2b	Description
Outcome	Variable	
Severe Preeclampsia	PEgHTN	Preeclampsia/Gestational hypertension
Superimposed		(HTN) (worst) using nuMoM2b criteria
Eclampsia		(CMDA08a)
Blood Product Transfusion	CMAE11	Any blood product transfusion anytime
		during pregnancy through 14 days
		postpartum
Postpartum Readmission	CMAJ01	Participant readmitted to the hospital within
		14 days of delivery

Table S2: Rates of adverse maternal outcomes in the nuMoM2b population overall and by race/ethnicity

	Non-Hispanic Non-Hispanic						
	Asian	Hispanic	Multiracial	Black	White	Other	Overall
	(N=342)	(N=1487)	(N=348)	(N=1145)	(N=5322)	(N=85)	(N=8729)
Blood Transfusion							
Yes	4 (1.2%)	37 (2.5%)	5 (1.4%)	29 (2.5%)	80 (1.5%)	2 (2.4%)	157 (1.8%)
No	338 (98.8%)	1449 (97.4%)	343 (98.6%)	1116 (97.5%)	5242 (98.5%)	83 (97.6%)	8571 (98.2%)
Missing	0 (0%)	1 (0.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.0%)
<b>Postpartum Readmission</b>							
Yes	1 (0.3%)	33 (2.2%)	8 (2.3%)	25 (2.2%)	84 (1.6%)	3 (3.5%)	154 (1.8%)
No	341 (99.7%)	1451 (97.6%)	340 (97.7%)	1119 (97.7%)	5230 (98.3%)	82 (96.5%)	8563 (98.1%)
Missing	0 (0%)	3 (0.2%)	0 (0%)	1 (0.1%)	8 (0.2%)	0 (0%)	12 (0.1%)
Severe Preeclampsia							
Yes	9 (2.6%)	52 (3.5%)	17 (4.9%)	76 (6.6%)	160 (3.0%)	4 (4.7%)	318 (3.6%)
No	332 (97.1%)	1431 (96.2%)	331 (95.1%)	1069 (93.4%)	5156 (96.9%)	81 (95.3%)	8400 (96.2%)
Missing	1 (0.3%)	4 (0.3%)	0 (0%)	0 (0%)	6 (0.1%)	0 (0%)	11 (0.1%)

# B.3 Study variables from the nuMoM2b dataset

52 53

Table S3: Pre-pregnancy conditions and their corresponding indicators in the nuMoM2b dataset

Condition		nuMoM2b
Туре	Pre-Pregnancy Condition	Variable
Acute Infection	Urinary tract infection	VXXB01am_V1a
Acute Infection	Sexually transmitted diseases, Gonorrhea	VXXB01bd1_V1a
Acute Infection	Sexually transmitted diseases, Chlamydia	VXXB01bd2_V1a
Acute Infection	Sexually transmitted diseases, Herpes	VXXB01bd3_V1a
Acute Infection	Sexually transmitted diseases, Syphilis	VXXB01bd4_V1a
Acute Infection	Sexually transmitted diseases, HIV/AIDS	VXXB01bd5_V1a
Acute Infection	Sexually transmitted diseases, Hepatitis B	VXXB01bd6_V1a
Acute Infection	Sexually transmitted diseases, Hepatitis C	VXXB01bd7_V1a
Acute Infection	Sexually transmitted diseases, Trichomonas	VXXB01bd8_V1a
Acute Infection	Sexually transmitted diseases, Other	VXXB01bd9_V1a
Acute Infection	Yeast infection	VXXB01be_V1a
Acute Infection	Bacterial vaginosis	VXXB01bf_V1a
Autoimmune	Systemic lupus erythematosus (SLE)	VXXB01au_V1a
Autoimmune	Rheumatoid arthritis	VXXB01av_V1a
Autoimmune	Other collagen vascular or autoimmune disease	VXXB01aw_V1a
Cancer	Cancer (malignancy)	VXXB01ba_V1a
Cardiovascular	High blood pressure (hypertension)	VXXB01aa_V1a
Cardiovascular	Valvular heart disease	VXXB01ah_V1a
Cardiovascular	Other structural heart disease	VXXB01ai_V1a
Cardiovascular	Coronary artery disease / congestive heart failure	VXXB01aj_V1a
Cardiovascular	Cardiac arrhythmias	VXXB01ak_V1a
Endocrine	Diabetes (excluding gestational diabetes in a prior pregnancy)	VXXB01ae_V1a
Endocrine	Hyperthyroidism	VXXB01af_V1a
Endocrine	Hypothyroidism	VXXB01ag_V1a
Gastrointestinal	Ulcerative colitis / Crohn's disease	VXXB01ax_V1a
Gastrointestinal	Liver/gall bladder disease	VXXB01az_V1a
Gynecological	Cervical dysplasia	VXXB01bc1_V1a
Gynecological	Fibroids	VXXB01bc2_V1a
Gynecological	Polycystic ovary disease (PCOS)	VXXB01bc3_V1a
Hematologic	Sickle cell disease	VXXB01an_V1a
Hematologic	Sickle cell trait	VXXB01ao_V1a

Hematologic	Thrombocytopenia	VXXB01ap_V1a
Hematologic	Anemia	VXXB01aq_V1a
	History of blood clots (thrombosis or thromboembolism) or	
Hematologic	stroke	VXXB01ar_V1a
Hematologic	Congenital or inherited bleeding disorder	VXXB01as_V1a
	Antiphospholipid syndrome (APA) or other acquired	
Hematologic	thrombophilia	VXXB01at_V1a
Kidney	Kidney disease	VXXB01al_V1a
Lung	Asthma	VXXB01ab_V1a
Mental	Mental health condition	VXXB01bb_V1a
Neurological	Seizure disorder	VXXB01ac_V1a
Neurological	Migraine headaches	VXXB01ad_V1a

In our analysis, we excluded the condition types: Acute Infection and Cancer. Acute infection is recorded as occurring anytime during a participant's life, which lacks relevance in our analysis because the nuMoM2b study did not collect the timing of the acute infection and because lifetime acute infections are common. Cancer was excluded due to its low prevalence.

Table S4: Prevalence of pre-pregnancy conditions by race in nuMoM2b dataset

Number of condition types is the sum of different condition types, for example, if a woman only has 2 cardiovascular conditions this is counted as 1 condition type

	Asian	Hispanic	Multiracial	Non-Hispanic Black	Non-Hispanic White	Other	Overall
Total	342 (3.9%)	1487 (17.0%)	348 (4.0%)	1145 (13.1%)	5322 (61.0%)	85 (1.0%)	8729 (100.0%)
Cardiovascular	20 (5.8%)	102 (6.9%)	43 (12.4%)	120 (10.5%)	459 (8.6%)	5 (5.9%)	749 (8.6%)
Lung	31 (9.1%)	174 (11.7%)	53 (15.2%)	181 (15.8%)	640 (12.0%)	12 (14.1%)	1091 (12.5%)
Neurological	31 (9.1%)	165 (11.1%)	37 (10.6%)	116 (10.1%)	778 (14.6%)	9 (10.6%)	1136 (13.0%)
Endocrine	40 (11.7%)	109 (7.3%)	15 (4.3%)	65 (5.7%)	494 (9.3%)	10 (11.8%)	733 (8.4%)
Kidney	2 (0.6%)	41 (2.8%)	2 (0.6%)	12 (1.0%)	97 (1.8%)	2 (2.4%)	156 (1.8%)
Hematologic	42 (12.3%)	223 (15.0%)	63 (18.1%)	221 (19.3%)	647 (12.2%)	10 (11.8%)	1206 (13.8%)
Autoimmune	6 (1.8%)	19 (1.3%)	5 (1.4%)	18 (1.6%)	121 (2.3%)	2 (2.4%)	171 (2.0%)
Gastrointestinal	5 (1.5%)	28 (1.9%)	7 (2.0%)	14 (1.2%)	116 (2.2%)	1 (1.2%)	171 (2.0%)
Mental	16 (4.7%)	144 (9.7%)	45 (12.9%)	95 (8.3%)	953 (17.9%)	8 (9.4%)	1261 (14.4%)
Gynecological	48 (14.0%)	126 (8.5%)	30 (8.6%)	82 (7.2%)	591 (11.1%)	8 (9.4%)	885 (10.1%)
Number of Condition Types							
0	181 (52.9%)	769 (51.7%)	161 (46.3%)	597 (52.1%)	2443 (45.9%)	44 (51.8%)	4195 (48.1%)
1	105 (30.7%)	435 (29.3%)	108 (31.0%)	319 (27.9%)	1552 (29.2%)	26 (30.6%)	2545 (29.2%)
2+	56 (16.4%)	283 (19.0%)	79 (22.7%)	229 (20.0%)	1327 (24.9%)	15 (17.6%)	1989 (22.8%)

Table S5: Prevalence of pre-pregnancy condition combined effects included in our analysis by race in nuMoM2b dataset

	Asian	Hispanic	Multiracial	Non-Hispanic Black	Non-Hispanic White	Other	Overall
Total	342 (3.9%)	1487 (17.0%)	348 (4.0%)	1145 (13.1%)	5322 (61.0%)	85 (1.0%)	8729 (100.0%)
Cardiovascular & Endocrine	2 (0.6%)	12 (0.8%)	2 (0.6%)	27 (2.4%)	64 (1.2%)	2 (2.4%)	109 (1.2%)
Cardiovascular & Gynecological	3 (0.9%)	10 (0.7%)	5 (1.4%)	20 (1.7%)	70 (1.3%)	1 (1.2%)	109 (1.2%)
Cardiovascular & Hematologic	2 (0.6%)	22 (1.5%)	12 (3.4%)	39 (3.4%)	84 (1.6%)	2 (2.4%)	161 (1.8%)
Cardiovascular & Neurological	2 (0.6%)	20 (1.3%)	9 (2.6%)	21 (1.8%)	99 (1.9%)	2 (2.4%)	153 (1.8%)
Endocrine & Hematologic	6 (1.8%)	23 (1.5%)	1 (0.3%)	22 (1.9%)	69 (1.3%)	1 (1.2%)	122 (1.4%)
Endocrine & Lung	3 (0.9%)	18 (1.2%)	2 (0.6%)	18 (1.6%)	83 (1.6%)	1 (1.2%)	125 (1.4%)
Gynecological & Hematologic	8 (2.3%)	26 (1.7%)	6 (1.7%)	33 (2.9%)	89 (1.7%)	1 (1.2%)	163 (1.9%)
Hematologic & Lung	4 (1.2%)	40 (2.7%)	9 (2.6%)	50 (4.4%)	111 (2.1%)	2 (2.4%)	216 (2.5%)
Lung & Neurological	8 (2.3%)	37 (2.5%)	11 (3.2%)	35 (3.1%)	153 (2.9%)	4 (4.7%)	248 (2.8%)
Mental & Neurological	5 (1.5%)	33 (2.2%)	8 (2.3%)	28 (2.4%)	248 (4.7%)	0 (0%)	322 (3.7%)

#### B.3 Model development details

The balancing class weight heuristic is inspired by King et al (2001) 40 and identical to scikit learn's "balanced" class weight function. The weights are given by the formula:

70 
$$w_i = \frac{number\ of\ total\ samples}{(number\ of\ classes)\cdot (number\ of\ i^{th}\ outcome)}$$

71 Where,

$$i = \begin{cases} 1 & \text{if adverse outcome occurred} \\ 0 & \text{otherwise} \end{cases}$$

- $number\ of\ total\ samples\ =\ 8729$
- $number\ of\ classes=2$

### 77 B.4 Mediation Analysis and Correlation

Firstly, each adverse maternal outcome was regressed individually by race/ethnicity, confounders, and potential mediators (all pre-pregnancy condition types and all their combined effects) (hereafter referred to as the "Outcome Model"), and only combined effects and their components reaching statistical significance (p-value ≤ 0.05) in this model were selected for further analysis. To analyze mediation, the selected potential mediator condition types and their combined effects were individually regressed by race/ethnicity and adjusted for confounders ("Mediator Model"). The Outcome and Mediator models were combined to compute average causal mediation effects (ACME) and total effect (TE) for each participant which was then averaged. Quasi-Bayesian estimation with 1,000 iterations was used to estimate the 95% CI and p-values of the natural indirect effect (NIE) and TE.<sup>23</sup> Mediation proportion, which estimates the proportion of the risk factor's impact on the outcome that is attributable to the mediator, was calculated as ACME / TE.<sup>23</sup> This analysis was conducted for each adverse maternal outcome and results were averaged across the five imputed datasets.

We assessed whether features were highly correlated and, a priori, planned to remove any that were highly correlated with another measure that was more relevant to our analysis to preserve the interpretability of the risk ratios. High correlation was indicated by a Pearson's coefficient absolute value of 0.70 or greater. No features, other than confounding factors, were highly correlated.

# **Appendix C: Results**

Table S6: AUC by race for each model and adverse maternal outcome.

AUC, area under the receiver operating characteristic curve

	Model 0	Model 1	Model 2	Model 3	Model 4
	Intercept	Race	(1) & Confounders	(2) & Condition Types	(3) & Condition Type Combined Effects
		Blo	od Transfusion, AUC		
Non-Hispanic White	0.49	0.50	0.51	0.58	0.58
Hispanic	0.49	0.50	0.50	0.50	0.51
Non-Hispanic Black	0.49	0.50	0.54	0.60	0.60
Multiracial	0.54	0.50	0.49	0.67	0.71
Asian	0.52	0.50	0.44	0.51	0.54
Other	0.58	0.90	0.63	0.52	0.52
Overall	0.49	0.56	0.55	0.59	0.59
		Postpa	rtum Readmission, AUC		
Non-Hispanic White	0.48	0.50	0.55	0.53	0.55
Hispanic	0.55	0.50	0.60	0.63	0.60
Non-Hispanic Black	0.52	0.50	0.59	0.59	0.57
Multiracial	0.57	0.55	0.53	0.59	0.54
Asian	0.76	0.50	0.50	0.50	0.50
Other	0.52	0.56	0.57	0.45	0.55
Overall	0.49	0.54	0.58	0.58	0.57
		Seve	re Preeclampsia, AUC		
Non-Hispanic White	0.50	0.50	0.59	0.62	0.63
Hispanic	0.49	0.47	0.58	0.69	0.68
Non-Hispanic Black	0.51	0.50	0.52	0.58	0.58
Multiracial	0.47	0.50	0.71	0.70	0.72
Asian	0.50	0.50	0.65	0.69	0.69
Other	0.45	0.67	0.51	0.49	0.38
Overall	0.50	0.56	0.61	0.65	0.65

98

99